Beikabuzukan
日本語
Watchlist

Seer, Inc.

Overview

Financials

Units: $M (per-share in $, ratios in %)

Revenue & profit

Margins

Valuation

Multiples at each fiscal year end (annual) and current (TTM)

Valuation history

Segments

Revenue breakdown (annual, $B). Segments depend on each year’s disclosure.

By product

By region

Dividends & earnings

Annual dividend per share ($, split-adjusted)

EPS (diluted), last 16 quarters ($)

Company info

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.